Published in Diabetes Care on July 01, 2010
Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4 | NCT00574340
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care (2014) 1.47
Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care (2010) 1.29
The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord (2012) 1.06
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care (2013) 1.03
Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice. Diabetes (2011) 0.98
Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol (2013) 0.97
Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care (2012) 0.96
A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia (2011) 0.95
Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. Diabetes Care (2013) 0.94
Proinflammatory and prothrombotic effects of hypoglycemia. Diabetes Care (2010) 0.91
Hypoglycemia as a driver of cardiovascular risk in diabetes. Curr Atheroscler Rep (2013) 0.89
Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. Diabetes (2015) 0.88
Hypoglycemia, but not glucose variability, relates to vascular function in children with type 1 diabetes. Diabetes Technol Ther (2012) 0.87
Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One (2011) 0.86
VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care (2013) 0.86
Altered Nrf2 signaling mediates hypoglycemia-induced blood-brain barrier endothelial dysfunction in vitro. PLoS One (2015) 0.85
Hypoglycemia in Type 2 Diabetes--More Common Than You Think: A Continuous Glucose Monitoring Study. J Diabetes Sci Technol (2015) 0.84
Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes. World J Diabetes (2015) 0.83
Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. Cardiovasc Diabetol (2013) 0.81
Mechanisms of hypoglycemia and exercise-associated autonomic dysfunction. Trans Am Clin Climatol Assoc (2014) 0.80
Hypoglycemia revisited in the acute care setting. Yonsei Med J (2011) 0.79
Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation (2017) 0.78
Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. Cardiovasc Diabetol (2015) 0.77
Comment on: Gruden et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 2012;35:1598-1604. Diabetes Care (2012) 0.76
Hypoglycemia and vascular disease. Clin Chem (2010) 0.76
A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care (2016) 0.75
Comparative effects of acute hypoglycemia and hyperglycemia on pro-atherothrombotic biomarkers and endothelial function in non-diabetic humans. J Diabetes Complications (2016) 0.75
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol (2017) 0.75
Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism (2016) 0.75
Update on strategies limiting iatrogenic hypoglycemia. Endocr Connect (2015) 0.75
Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf (2016) 0.75
Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res (2017) 0.75
Association of self-reported recurrent mild hypoglycemia with incident cardiovascular disease and all-cause mortality in patients with type 2 diabetes: Prospective analysis of the Joint Asia Diabetes Evaluation Registry. Medicine (Baltimore) (2016) 0.75
IL-6 and type 1 diabetes mellitus: T cell responses and increase in IL-6 receptor surface expression. Ann Transl Med (2017) 0.75
The role of bile acid sequestrants in the management of type 2 diabetes mellitus. Metab Syndr Relat Disord (2010) 0.75
Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus. Sci Rep (2017) 0.75
Energetic stress: The reciprocal relationship between energy availability and the stress response. Physiol Behav (2015) 0.75
Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. Circulation (2017) 0.75
Type 1 Diabetes: Urinary Proteomics and Protein Network Analysis Support Perturbation of Lysosomal Function. Theranostics (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med (2001) 4.07
The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care (1985) 3.48
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care (1994) 2.56
Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med (1987) 2.30
Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev (2008) 2.28
Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism (2009) 1.67
Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. Circulation (2000) 1.24
Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab (1999) 1.19
Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care (2008) 1.18
Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care (2003) 1.16
Insulin infusion in acute illness. J Clin Invest (2005) 1.10
Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta (2008) 1.06
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia? Diabet Med (1991) 0.96
Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes (1986) 0.93
Endothelium, inflammation, and diabetes. Curr Diab Rep (2002) 0.89
Cortical blindness and cerebral infarction associated with severe hypoglycemia. Diabetes Care (1996) 0.86
Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol (2007) 0.83
The effect of insulin-induced hypoglycaemia on factor VIII:C concentrations and thrombin activity in subjects with type 1 (insulin-dependent) diabetes. Thromb Haemost (1995) 0.83
Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sci (Lond) (1993) 0.81
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
Autonomic contribution to blood pressure and metabolism in obesity. Hypertension (2006) 2.25
Postural pseudoanemia: posture-dependent change in hematocrit. Mayo Clin Proc (2005) 1.89
Human muscle sympathetic neural and haemodynamic responses to tilt following spaceflight. J Physiol (2002) 1.56
The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29
Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes (2004) 1.20
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Analysis of raw microneurographic recordings based on wavelet de-noising technique and classification algorithm: wavelet analysis in microneurography. IEEE Trans Biomed Eng (2003) 1.16
Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab (2011) 1.11
Influence of microgravity on astronauts' sympathetic and vagal responses to Valsalva's manoeuvre. J Physiol (2002) 1.08
Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2006) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Leptin: metabolic control and regulation. J Diabetes Complications (2003) 1.03
Human cerebral autoregulation before, during and after spaceflight. J Physiol (2006) 1.03
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes (2003) 1.01
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs (2014) 1.00
Cardiovascular and sympathetic neural responses to handgrip and cold pressor stimuli in humans before, during and after spaceflight. J Physiol (2002) 0.99
Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes (2003) 0.98
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes (2008) 0.97
Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium: relevance to therapeutic preconditioning in humans. Circulation (2003) 0.95
Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone (2006) 0.93
Influence of vestibular activation on respiration in humans. Am J Physiol Regul Integr Comp Physiol (2002) 0.91
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes (2008) 0.90
Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev (2005) 0.89
Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes (2003) 0.89
Hypoglycemia associated autonomic failure. Clin Auton Res (2002) 0.88
Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.87
Baroreflex physiology studied in healthy subjects with very infrequent muscle sympathetic bursts. J Appl Physiol (1985) (2012) 0.87
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Curr Diabetes Rev (2013) 0.87
Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. Diabetes (2010) 0.86
Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother (2011) 0.86
Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab (2006) 0.85
Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care (2010) 0.85
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes. Diabetes (2009) 0.85
Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia. Am J Physiol Endocrinol Metab (2008) 0.84
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2015) 0.84
Effect of sex on counterregulatory responses to exercise after antecedent hypoglycemia in type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 0.84
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications (2007) 0.84
Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes. J Clin Endocrinol Metab (2002) 0.84
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats. Am J Physiol Endocrinol Metab (2007) 0.83
Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab (2005) 0.83
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2013) 0.82
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol (2011) 0.82
Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther (2011) 0.82
NO synthase inhibition increases aldosterone in humans. Hypertension (2004) 0.82
The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2010) 0.82
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther (2012) 0.81
Lower-body negative-pressure exercise and bed-rest-mediated orthostatic intolerance. Med Sci Sports Exerc (2002) 0.81
The effects of dehydroepiandrosterone sulfate on counterregulatory responses during repeated hypoglycemia in conscious normal rats. Diabetes (2004) 0.80
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.79
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am J Physiol Endocrinol Metab (2005) 0.79
Caffeine: a cause of insulin resistance? Diabetes Care (2002) 0.78
Physical activity in adolescents with type 1 diabetes: is more better for glycemic control? Pediatr Diabetes (2009) 0.78
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep (2008) 0.78
Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab (2008) 0.77
Hypoglycemia and vascular disease. Clin Chem (2010) 0.76
Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract (2004) 0.76
New concepts in diabetes: how multihormonal regulation can improve glycemic control. J Manag Care Pharm (2004) 0.76
Diabetes: Hypoglycemia-a new approach to an old problem. Nat Rev Endocrinol (2009) 0.76
Metabolic consequences of exercise-associated autonomic failure. Exerc Sport Sci Rev (2006) 0.76
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2012) 0.76
Forebrain and hindbrain effects of ethanol on counterregulatory responses to hypoglycemia in conscious rats. Metabolism (2007) 0.75
Discontinued in 2013: diabetic drugs. Expert Opin Investig Drugs (2014) 0.75
The cardiovascular effects of insulin. Expert Opin Drug Saf (2014) 0.75
Prior exercise and the response to insulin-induced hypoglycemia in the dog. Am J Physiol Endocrinol Metab (2002) 0.75
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation. Clin Cornerstone (2006) 0.75
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2014) 0.75
Leptin responses to antecedent exercise and hypoglycemia in healthy and type 1 diabetes mellitus men and women. J Diabetes Complications (2003) 0.75
The endocannabinoid system as a target for obesity treatment. Clin Cornerstone (2008) 0.75